Research Update

RNS Number:4138L
Amarin Corporation Plc
09 January 2008






          AMARIN ANNOUNCES SUCCESSFUL OUTCOME OF NASAL LORAZEPAM STUDY


LONDON, United Kingdom, January 9, 2008 - Amarin Corporation plc (NASDAQ: AMRN)
today announced the successful completion of a preclinical proof of concept
study using a novel nasal formulation of lorazepam. The preclinical study
evaluated the extent of absorption of lorazepam after nasal administration and
the pharmacokinetics of the novel formulation. Amarin is now working with a
subsidiary of Elan Corporation, plc (NYSE: ELN) to prepare this nasal
formulation for human pharmacokinetic trials.

This nasal lorazepam formulation utilizes Elan's proprietary NanoCrystal(R)
Technology and is in development for the out-patient treatment of emergency
seizures in epilepsy patients, specifically status epilepticus and acute
repetitive seizures.

About Status Epilepticus and Acute Repetitive Seizures

A seizure emergency is a prolonged seizure or continuous state of frequently
occurring seizures. One common type of seizure emergency is called status
epilepticus (SE). SE may be defined as a prolonged seizure lasting longer than
10 minutes. SE is also defined by a series of repeated seizures without the
return of consciousness between seizures. SE has an annual incidence estimated
at approximately 150,000 cases in the United States alone with approximately
40,000 deaths per year.


Another type of seizure emergency is acute repetitive seizures (ARS), which is a
bout or cluster of seizures over a short period of time in which the patient
regains consciousness between seizures.  It is estimated that up to 400,000
people in the United States suffer from ARS.

Epilepsy is a very common disorder affecting approximately 0.5% of the
population and is characterized by seizures, which may vary from the briefest
lapses of attention to muscle jerks to severe and prolonged convulsions. They
may also vary in frequency, from less than one a year to several per day.

About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system and cardiovascular diseases. Our goal is to be a leader in the
research, development and commercialization of novel drugs that address unmet
patient needs.


Amarin's CNS development pipeline includes the recently acquired myasthenia
gravis clinical program and preclinical programs in neuromuscular, neuronal
degenerative and inflammatory diseases; Miraxion for Huntington's disease; two
programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is
initiating a series of cardiovascular preclinical and clinical programs to
capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin also has two proprietary technology platforms, a
lipid-based technology platform for the targeted transport of molecules through
the liver and/or to the brain, and a unique mRNA technology based on cholinergic
neuromodulation.


Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively.



Contacts:

Amarin

Thomas Lynch, Chairman and Chief Executive Officer, [phone]

Alan Cooke, President and Chief Operating Officer, [phone]

[e-mail]


Investors:

Lippert/Heilshorn & Associates, Inc.

Anne Marie Fields [phone]

Bruce Voss [phone]


Media:

Powerscourt [phone]

Rory Godson

Paul Durman

Sarah Daly


Disclosure Notice

The information contained in this document is as of January 9, 2008. Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: risks relating to the Company's ability to maintain its Nasdaq
listing (including the risk that the Company may not successfully appeal a
Nasdaq delisting determination); Amarin's ability to maintain sufficient cash
and other liquid resources to meet its operating requirements; the success of
Amarin's research and development activities, including its planned clinical
trials in cardiovascular disease and; decisions by regulatory authorities
regarding whether and when to approve Amarin's drug applications, as well as
their decisions regarding labeling and other matters that could affect the
commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
general changes in International and US generally accepted accounting
principles; and growth in costs and expenses. A further list and description of
these risks, uncertainties and other matters can be found in Amarin's Form 20-F
for the fiscal year ended December 31, 2006, filed with the SEC on March 5,
2007, Amarin's statutory annual report for the year ended 31 December, 2006
furnished on a Form 6-K to the SEC on May 9, 2007 and in its Reports of Foreign
Issuer on Form 6-K furnished to the SEC.


                                     # # #








                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RESSSEFEUSASEFF